TUCSON, Ariz. – June 14, 2021 – Avery Therapeutics, Inc. (Avery), a privately held, pre-clinical stage therapeutics company announced today that it has completed a Pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA). Avery received FDA feedback on its planned manufacturing and IND-enabling studies for its novel therapeutic candidate, MyCardia™, which is in development for the treatment of ischemic heart failure.Continue reading
Author Archive: AZBio
Largescale brain epigenetics study provides new insights into dementia
The largest study of its kind has unveiled new insights into how genes are regulated in dementia, including discovering 84 new genes linked to the disease.
Continue reading
The Future of Phoenix is Bioscience
Phoenix steps into the spotlight on the Innovation Stage. BIO Digital is virtually bringing together more than 5,000 participants from 55 countries for BIO One-on-One Partnering, critical education and networking starting June 10-11 with the new Innovation Stage and Phoenix is there.Continue reading
PFIZER AND BIONTECH TO PROVIDE 500 MILLION DOSES OF COVID-19 VACCINE TO U.S. GOVERNMENT FOR DONATION TO POOREST NATIONS
- U.S. government to purchase at not-for-profit price 200 million doses in 2021 and 300 million in the first half of 2022
- Doses to be donated to approximately 100 low- and lower middle-income countries including those in the African Union via the COVAX Facility
- Effort is part of the companies’ recent pledge of two billion doses to ensure global equitable access to the vaccine
Accelerate Diagnostics Receives CARB-X Award to Develop Rapid Optical Imaging Technology for Sepsis and Antibiotic-Resistant Infections
CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to accelerating research and development to address the rising global threat of drug-resistant bacteria, has awarded Accelerate Diagnostics up to $578,000 to develop new fiber optic technology to diagnose sepsis or the risk of sepsis. Accelerate would be eligible for up to $2.1 million in additional funds from CARB-X if the project meets certain milestones.Continue reading
Arizona Bioindustry Association Earns GuideStar’s Highest Seal of Transparency Again in 2021
The Arizona Bioindustry Association(AZBio) has earned a 2021 Platinum Seal of Transparency, the highest level of recognition offered by GuideStar, the world’s largest source of nonprofit information. Continue reading
FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease
The accumulation of amyloid beta plaques in the brain is a defining pathology of Alzheimer’s disease
In clinical trials, ADUHELM reduced amyloid beta plaques by 59 to 71 percent at 18 months of treatmentContinue reading
Ivy Brain Tumor Center Announces Interim Results from a Phase 0 ‘Trigger’ Trial of Targeted Combination Therapy for Glioblastoma
Results to be presented at 2021 ASCO Annual Meeting demonstrate that Abemaciclib and LY3214996 achieve pharmacologically-relevant concentrations in Gd-non-enhancing GBM tissue • Ongoing study will accrue an additional 25 patients at the Optimal Time Interval (OTI) identified for tissue samplingContinue reading
The Generate Life Sciences Family of Companies Grows With the Addition of the Cell Care Group of Cord Blood Banks
The acquisition provides the companies with shared scientific knowledge and resources, leading to a stronger foundation for advancing newborn stem cell researchContinue reading
Health-care entrepreneur joins Flinn Foundation board
Heidi Jannenga, one of Arizona’s most accomplished health-care-technology entrepreneurs, has been elected to the Flinn Foundation board of directors. Continue reading